The Scottish Medicines Consortium (SMC) has issued its monthly advice on new medicines.
Fampridine (Fampyra®) has been rejected for use to improve walking in adult patients with multiple sclerosis with walking disability. The manufacturer failed to make a submission. The manufacturer already recommends that use is restricted to prescription and supervision by physicians experienced in the management of multiple sclerosis.
Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.
|« BNF 63||Reappraisal of Metformin »|